Form 4 for ABBV AbbVie
Accepted 2026-02-20 00:00:00 ET · period of report 2026-02-18 · accession 0001563545-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-20 | 2026-02-18 | ABBV | SALEKI-GERHARDT AZITA | EVP, Chief Ops Off | A - Grant | $0.00 | +36.8K | 214.1K | +21% | $0 |
| D | 2026-02-20 | 2026-02-18 | ABBV | SALEKI-GERHARDT AZITA | EVP, Chief Ops Off | A - Grant | $0.00 | +20.3K | 20.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 par value | 2026-02-18 | A | A | 6,058 | $0.00 | 200,391 | D | — | — | (F2) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. |
| 2 | Common | Common Stock, $0.01 par value | 2026-02-18 | A | A | 17,041 | $0.00 | 194,333 | D | — | — | (F1) Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. |
| 3 | Common | Common Stock, $0.01 par value | 2026-02-18 | A | A | 7,074 | $0.00 | 207,465 | D | — | — | (F3) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. |
| 4 | Common | Common Stock, $0.01 par value | 2026-02-18 | A | A | 6,638 | $0.00 | 214,103 | D | — | — | (F4) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. |
| 5 | Derivative | Option (Right to Buy) | 2026-02-18 | A | A | 20,312 | $0.00 | 20,312 | D | $230.04 · — to 2036-02-17 | 20,312 Common Stock | (F7) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029. |